Kuo Ying-Yu, Jim Wai-Tim, Su Liang-Cheng, Chung Chi-Jung, Lin Ching-Yu, Huo Chieh, Tseng Jen-Chih, Huang Shih-Han, Lai Chih-Jen, Chen Bo-Chih, Wang Bi-Juan, Chan Tzu-Min, Lin Hui-Ping, Chang Wun-Shaing Wayne, Chang Chuang-Rung, Chuu Chih-Pin
Institute of Cellular and System Medicine, National Health Research Institutes, Miaoli 35053, Taiwan.
Institute of Biotechnology, National Tsing Hua University, Hsinchu City 30013, Taiwan.
Int J Mol Sci. 2015 May 12;16(5):10748-66. doi: 10.3390/ijms160510748.
Head and neck cancers, which affect 650,000 people and cause 350,000 deaths per year, is the sixth leading cancer by cancer incidence and eighth by cancer-related death worldwide. Oral cancer is the most common type of head and neck cancer. More than 90% of oral cancers are oral and oropharyngeal squamous cell carcinoma (OSCC). The overall five-year survival rate of OSCC patients is approximately 63%, which is due to the low response rate to current therapeutic drugs. In this review we discuss the possibility of using caffeic acid phenethyl ester (CAPE) as an alternative treatment for oral cancer. CAPE is a strong antioxidant extracted from honeybee hive propolis. Recent studies indicate that CAPE treatment can effectively suppress the proliferation, survival, and metastasis of oral cancer cells. CAPE treatment inhibits Akt signaling, cell cycle regulatory proteins, NF-κB function, as well as activity of matrix metalloproteinase (MMPs), epidermal growth factor receptor (EGFR), and Cyclooxygenase-2 (COX-2). Therefore, CAPE treatment induces cell cycle arrest and apoptosis in oral cancer cells. According to the evidence that aberrations in the EGFR/phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling, NF-κB function, COX-2 activity, and MMPs activity are frequently found in oral cancers, and that the phosphorylation of Akt, EGFR, and COX-2 correlates to oral cancer patient survival and clinical progression, we believe that CAPE treatment will be useful for treatment of advanced oral cancer patients.
头颈癌每年影响65万人，并导致35万人死亡，在全球癌症发病率中位列第六，在癌症相关死亡率中位列第八。口腔癌是头颈癌最常见的类型。超过90%的口腔癌为口腔和口咽鳞状细胞癌（OSCC）。OSCC患者的总体五年生存率约为63%，这是由于对当前治疗药物的低反应率所致。在本综述中，我们讨论了使用咖啡酸苯乙酯（CAPE）作为口腔癌替代治疗方法的可能性。CAPE是一种从蜜蜂蜂巢蜂胶中提取的强抗氧化剂。最近的研究表明，CAPE治疗可有效抑制口腔癌细胞的增殖、存活和转移。CAPE治疗可抑制Akt信号传导、细胞周期调节蛋白、NF-κB功能，以及基质金属蛋白酶（MMPs）、表皮生长因子受体（EGFR）和环氧化酶-2（COX-2）的活性。因此，CAPE治疗可诱导口腔癌细胞的细胞周期停滞和凋亡。鉴于在口腔癌中经常发现EGFR/磷脂酰肌醇3-激酶（PI3K）/蛋白激酶B（Akt）信号传导、NF-κB功能、COX-2活性和MMPs活性异常，且Akt、EGFR和COX-2的磷酸化与口腔癌患者的生存和临床进展相关，我们认为CAPE治疗将有助于治疗晚期口腔癌患者。
